StreetInsider.com News Articles

MitoCareX Bio begins early-stage review of protein sourcing methods

Wed, 23 Sep 2026 07:09:00 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly-owned subsidiary, MitoCareX Bio Ltd., is evaluating additional commercially available approaches for obtaining proteins used in its in-vitro research activities.

The evaluation focuses on established methods for sourcing proteins and aims to determine whether these approaches meet MitoCareX's research requirements. The company said the assessment is intended to broaden research tools available for its in-vitro activities and maintain flexibility as its drug discovery programs advance.

According to the announcement, the evaluation remains at an early stage. The company noted there is no assurance that any approach under consideration will be adopted or provide anticipated

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Wed, 23 Sep 2026 07:07:00 -0400

Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs

Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. , (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that its wholly-owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), a drug discovery company, is evaluating additional approaches for obtaining proteins used in its in-vitro research activities.

MitoCareX is evaluating established, commercially available approaches for obtaining proteins

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Wed, 23 Sep 2026 07:07:00 -0400

MitoCareX is evaluating established, commercially available approaches for obtaining proteins

Form 10-Q Nexentis Technologies For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920940.html

Form 10-Q Nexentis Technologies For: Jun 30

Thu, 13 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260813/26920940.html

Form 8-K Nexentis Technologies For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883732.html

Form 8-K Nexentis Technologies For: Aug 06

Thu, 06 Aug 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26883732.html

MitoCareX Bio selects SLC transport protein for drug discovery

Tue, 28 Jul 2026 08:06:38 -0400

Nexentis Technologies Inc. (NASDAQ: NXTS) announced that its wholly owned subsidiary, MitoCareX Bio Ltd., has selected a transport protein candidate for a drug discovery campaign, according to a press release dated July 28, 2026.

MitoCareX completed an internal prioritization process to narrow its focus from a broader pool of SLC transport protein candidates previously identified through structural analysis. The selected candidate was identified as having favorable characteristics for inclusion in a drug discovery campaign.

The selection follows a structural analysis of the human SLC transport protein family that MitoCareX conducted outside its mitochondrial program. The company identified proteins it determined were compatible

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE^®-driven discovery strategy

Ness Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has narrowed its focus from the broader pool of SLC transport protein

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Tue, 28 Jul 2026 08:06:00 -0400

Form EFFECT Nexentis Technologies

Mon, 20 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26786524.html

Form EFFECT Nexentis Technologies

Mon, 20 Jul 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260720/26786524.html

Form EFFECT Nexentis Technologies

Thu, 16 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260716/26776037.html

Form EFFECT Nexentis Technologies

Thu, 16 Jul 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260716/26776037.html

Form SCHEDULE 13G/A Nexentis Technologies Filed by: Lee Eun Young

Wed, 15 Jul 2026 13:56:00 -0400

si-local-file:///var/storage/secattach/20260715/26773533.html

Form SCHEDULE 13G/A Nexentis Technologies Filed by: Lee Eun Young

Wed, 15 Jul 2026 13:56:00 -0400

si-local-file:///var/storage/secattach/20260715/26773533.html

Nexentis Technologies (NXTS) files for 2.57M share offering by selling stockholders

Mon, 13 Jul 2026 16:08:20 -0400

Nexentis Technologies (NASDAQ: NXTS) has filed for up to 2,572,874 share offering by selling stockholders.

Nexentis Technologies (NXTS) files for 2.57M share offering by selling stockholders

Mon, 13 Jul 2026 16:08:20 -0400

Nexentis Technologies (NASDAQ: NXTS) has filed for up to 2,572,874 share offering by selling stockholders.

Form S-1 Nexentis Technologies

Mon, 13 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26762507.html

Form S-1 Nexentis Technologies

Mon, 13 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260713/26762507.html

Form POS AM Nexentis Technologies

Mon, 13 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260713/26762495.html

Form POS AM Nexentis Technologies

Mon, 13 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260713/26762495.html

Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative

Tue, 07 Jul 2026 08:25:00 -0400

MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Boltz

Ness Ziona, Israel, July 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, has recently reported that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX Bio”), successfully completed a broad analysis of SLC